PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
July 23, Chicago – PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma…
PolyActiva commences its first Phase I clinical trial
PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is safe and well tolerated…
PolyActiva raises AUD$9.2M in Series B venture funding
PolyActiva announced today that it has raised AUD $9.2 Million in a Series B financing round from a consortium of investors including the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capital), Yuuwa Capital and additional participation from angel investors.
New funding to commercialise medical research in Victoria
Victorian Minister for Technology Gordon Rich-Phillips today announced new funding of $1.6 million from the Victorian Government to support the operation of the Medical Research Commercialisation Fund (MRCF) over the next four years. An example of an innovative business benefiting from the MRCF is PolyActiva…